C1563738||Oncolytic Virotherapy
C0027150||Myxoma Virus
C0398533||Allogeneic Bone Marrow Transplant
C0023516||Leukocytes
C0600555||Graft versus Tumor
C4255274||Allogeneic stem cell transplant
C0039194||T cells
C0242594||residual cancer
C1708063||primary therapy
C0027150||myxoma virus
C0027150||myxoma virus
C0003392||anti-cancer
C1707887||efficacy
C0086418||human
C0027651||cancers
C0026764||multiple myeloma
C0026764||multiple myeloma
C0040732||transplant
C0039194||T cells
C0027651||cancer
C1752435||killers
C0027150||myxoma virus
C1563738||virotherapy
C0025929||murine
C0026764||multiple myeloma
C1512656||immunocompetent
C0025929||mice
C2986594||allogeneic mouse-mouse model
C0682523||human MM cell lines
C1513528||murine MM cell line
C0027150||myxoma virus
C3714514||infection
C0333516||oncolysis
C0027150||myxoma virus
C0149615||allogeneic bone marrow (BM) transplantation
C0026764||multiple myeloma
C1515655||in vivo
C0027950||neutrophils
C0039194||T cells
C0007613||donor function
C0007634||virus-armed carrier cells
C0027150||myxoma virus
C0007634||cells
C0026764||multiple myeloma
C1752435||killing
C0242594||residual cancer
C0040739||allotransplant
C0023516||leukocytes
C0027150||myxoma virus
C0600555||graft-versus-tumor effects